Triiodothyronine partly rescued the chondrocytes from cytotoxicity caused by HT-2. HT-2 toxin appeared to effectively induce the switch of the chondrocytes into pre-hypertrophic state.

1. Introduction {#sec1-toxins-11-00667}
===============

Thyroid hormone (triiodothyronine, T~3~) is converted to this active form from thyroxine (T~4~) by deiodinase 2 (DIO2), and it is known to be an essential regulator in metabolism, growth, and development of the human body, and it is critical for the maturation of the skeletal system \[[@B1-toxins-11-00667]\]. It controls the linear growth of bone by regulating endochondral ossification and promotes chondrocyte maturation and hypertrophic differentiation \[[@B2-toxins-11-00667]\]. It has also been exploited to enhance cartilage formation and improve the functional properties of tissue-engineered neocartilage \[[@B3-toxins-11-00667]\]. Furthermore, T~3~ enhances chondrogenesis of mesenchymal stem cells of the umbilical cord \[[@B4-toxins-11-00667]\]. In addition, T~3~ regulates the transition between proliferation and terminal differentiation of chondrocytes in the growth plate via the *Wnt/β-catenin* signaling pathway \[[@B5-toxins-11-00667],[@B6-toxins-11-00667]\]. Thus, a body of evidence implies that T~3~ has significant effects on cartilage and chondrocyte physiology. It is worth mentioning that up-regulated *DIO2* expression has been observed in osteoarthritic human articular cartilage and transgenic mice overexpressing *DIO2* \[[@B7-toxins-11-00667]\]. Moreover, low serum T~3~ syndrome led to DIO2 dysfunction in Kashin-Beck disease (KBD) children \[[@B8-toxins-11-00667],[@B9-toxins-11-00667]\].

T-2 and HT-2 toxins are two of the most representative and toxic members of the trichothecenes family, which are widely present in cereal grains and other cereal-based products, and are produced by various fungi species, such as Fusarium \[[@B10-toxins-11-00667]\]. In rats, T-2 and HT-2 toxins were mainly distributed in the skeletal system at significantly higher concentrations than those in other organs \[[@B11-toxins-11-00667]\]. In addition, the HT-2 toxin was shown to be a detectable metabolite of T-2 toxin in human chondrocytes, although it was deduced to be less toxic than T-2 \[[@B12-toxins-11-00667]\]. After ingestion, the T-2 toxin is converted into more than 20 metabolites in animals \[[@B13-toxins-11-00667]\]. The T-2 toxin is a cytotoxic fungal secondary metabolite produced by various species of Fusarium, and it interferes especially with the immune system, can harm fetal tissues, and induces cell death by apoptosis \[[@B13-toxins-11-00667]\]. Furthermore, both the T-2 toxin and HT-2 toxin can result in apoptosis of chondrocytes by increased oxidative stress, which causes a release of *Bax*, *caspase-3*, and *caspase-9* \[[@B14-toxins-11-00667]\]. A number of studies have reported that the T-2 toxin induces chondrocytes' apoptosis, promotes catabolism and intracellular impairment of cartilage, and is a risk factor of KBD \[[@B15-toxins-11-00667],[@B16-toxins-11-00667],[@B17-toxins-11-00667]\]. However, studies on the direct effects of the HT-2 toxin on cartilage and chondrocytes are still missing.

It is important to clarify the potentially damaging effect of the HT-2 toxin on human chondrocytes to enrich our knowledge of the possible molecular mechanisms of the HT-2 toxin causing cartilage lesions observed in KBD. Furthermore, this study aimed to explore whether T~3~ can protect from the chondrocytic injury caused by the HT-2 toxin in vitro, which may contribute to the combined effects both on cartilage and the potential pathogenesis of KBD. The concurrence of the abnormal T~3~ level and HT-2 toxin in vivo of KBD prompted this study to explore the effect of T~3~ and the HT-2 toxin on C-28/I2 chondrocytes and their combined effects.

2. Results {#sec2-toxins-11-00667}
==========

2.1. Individual Cytotoxicity of T~3~ and HT-2 Toxin in Human C-28/I2 Chondrocytes {#sec2dot1-toxins-11-00667}
---------------------------------------------------------------------------------

MTT assay was used to evaluate the cytotoxicity in C-28/I2 chondrocyte cultures treated with T~3~ at concentrations ranging from 0 to 1000 nM. T~3~ was found to produce no major effect on the cell viability of C-28/I2 chondrocytes, even at 1000 nM concentration, although a statistically significant difference was observed at 50 nM ([Figure 1](#toxins-11-00667-f001){ref-type="fig"}A). In contrast, HT-2 was highly toxic to C-28/I2 cells, especially at concentrations ≥ 50 nM ([Figure 1](#toxins-11-00667-f001){ref-type="fig"}B).

2.2. T~3~ Protects against HT-2 Toxin-Induced Toxicity {#sec2dot2-toxins-11-00667}
------------------------------------------------------

Mixtures of HT-2 toxin and T~3~ at different concentration ratios of both were tested following 24-hour-long exposures. In general, HT-2 concentrations ≥50 nM significantly decreased the cell viability in comparison to control cultures ([Figure 2](#toxins-11-00667-f002){ref-type="fig"}). However, at equimolar concentrations, it took a 100 nM concentration of HT-2 to result in a significant decrease in the cell viability ([Figure 2](#toxins-11-00667-f002){ref-type="fig"}A). Also, when T~3~ was present at higher molar ratios in relation to HT-2, cytotoxicity was obvious at HT-2 toxin concentrations ≥50 nM ([Figure 2](#toxins-11-00667-f002){ref-type="fig"}B,C). At the ratio 1:1000, HT-2 concentration did not reach 50 nM concentration, and no decrease in cell viability was observed ([Figure 2](#toxins-11-00667-f002){ref-type="fig"}D).

When the molar concentration of HT-2 toxin was higher than T~3~, a decrease in the cell viability due to HT-2 toxin was obvious starting from 50 nM concentrations ([Figure 2](#toxins-11-00667-f002){ref-type="fig"}E--G). However, the addition of T~3~ could partially rescue the effect of HT-2 toxin on cell viability ([Figure 2](#toxins-11-00667-f002){ref-type="fig"}E). At high molar ration of HT-2 toxin, T~3~ did not have a protective effect on cell viability ([Figure 2](#toxins-11-00667-f002){ref-type="fig"}F,G). The dose-effect plot of all ratios generated by CompuSyn software is shown as the [Figure S1](#app1-toxins-11-00667){ref-type="app"}.

2.3. Expressions of Extracellular Matrix and Hypertrophy Related-Genes in Chondrocyte Cultures Treated with T~3~ and/or HT-2 Toxin {#sec2dot3-toxins-11-00667}
----------------------------------------------------------------------------------------------------------------------------------

The expression levels of four chondrocyte phenotype-related genes (*aggrecan*, *collagen types II* and *X*, and *runx2*) were quantified in C-28/I2 chondrocytes treated with 50 nM T~3~, 50 nM T~3~ plus 50 nM HT-2 toxin, or 50 nM HT-2 for 24 h. Compared with the control group, 50 nM T~3~ did not produce any significant changes in the gene expression levels of *collagen types II* and *X*, *aggrecan*, or *runx2* ([Figure 3](#toxins-11-00667-f003){ref-type="fig"}). The expression level of *aggrecan* was significantly increased in the presence of the HT-2 toxin (*p* \< 0.05), and the level of *collagen type II* was 2-fold higher than the control ([Figure 3](#toxins-11-00667-f003){ref-type="fig"}). For the combination treatment of T~3~ and HT-2, gene expression patterns were similar to those by the HT-2 toxin alone ([Figure 3](#toxins-11-00667-f003){ref-type="fig"}).

It is well known that runx2 is a crucial transcription factor for chondrocyte maturation, and it induces the expression of *type X collagen* during the maturation process \[[@B18-toxins-11-00667]\]. Thus, it was expected that T~3~, which takes part in hypertrophic differentiation, would increase the expression of *runx2* and *collagen type X*. However, neither were affected by T~3~ ([Figure 3](#toxins-11-00667-f003){ref-type="fig"}). Surprisingly, the HT-2 toxin significantly increased gene expression of *runx2*, although *type X collagen* expression remained unchanged from control levels. Immunoblot analysis was performed to confirm the induction of runx2 at the protein level. Indeed, immunoblotting confirmed the induced expression of runx2 produced by HT-2 ([Figure 4](#toxins-11-00667-f004){ref-type="fig"}). A slight, but not significant, increase in runx2 level was also observed for the T~3~ treatment. In conclusion, chondrocytes apparently reached the pre-hypertrophic stage in the presence of HT-2, while T~3~ could not promote this in the relatively short, 24-h-long time of the experiment. The indication that HT-2 would be such a strong inducer of runx2 expression was surprising.

3. Discussion {#sec3-toxins-11-00667}
=============

It is well known that T~3~ has an important role in growth plate maturation and development \[[@B1-toxins-11-00667],[@B2-toxins-11-00667]\] and that inhibition of the T~3~ response by dominant-negative nuclear receptors promotes defects in cartilage maturation, ossification, and bone mineralization \[[@B19-toxins-11-00667]\]. The regulation of T~3~ is particularly important during growth, which is the time when aberrations in endochondral ossification and growth occur in KBD \[[@B20-toxins-11-00667]\]. Mycotoxins T-2 and its metabolite HT-2 have been shown to accumulate especially in the skeletal tissues \[[@B11-toxins-11-00667]\], and they have been considered as possible factors for the KBD.

In this study, the cytotoxicities of T~3~ and the HT-2 toxin alone were first examined. At most, a very weak T~3~-mediated cytotoxicity in C-28/I2 chondrocytes was noticed, even at a non-physiologically high dose following 24-h of exposure. Also, a longer, 72-h-treatment, changed the response only minimally. In contrast, the HT-2 toxin had a cytotoxic effect on human chondrocytes at a 50 nM concentration after 24-h-exposure. In growth plate chondrocytes, long-term exposure to T~3~ inhibits cellular proliferation, which obviously is also related to hypertrophic differentiation \[[@B1-toxins-11-00667]\].

When HT-2 toxin and T~3~ were administered at equal concentrations, the concentration to induce a statistically significant decrease in cell viability was shifted from 50 nM to 100 nM, indicating a protective effect of T~3~ on cytotoxicity induced by the HT-2 toxin. This led us to investigate how different molar ratios of the HT-2 toxin and T~3~ affect chondrocyte viability. When the ratio of HT-2:T~3~ was 10:1, HT-2 toxin concentrations ≥50 nM caused a significantly reduced cell viability, which was partly rescued by T~3~. At ratios 100:1 and 1000:1, there were no obvious combined effects on cell viability.

Therefore, although T~3~ helped to reduce the cytotoxicity produced by the HT-2 toxin to human chondrocytes, it was most effective at an HT-2 toxin concentration range of 50--100 nM. However, the mechanism of the protective effect of T~3~ to chondrocyte death still remains unknown. In sheep growth plate chondrocytes, it has been shown that T~3~ is linked to chondrocyte proliferative capacity by targeted *FGFR3* to regulate telomerase reverse transcriptase expression and telomerase activity \[[@B21-toxins-11-00667]\]. Also, the bone morphogenetic protein pathway has been implicated to be essential for the function of T~3~ in chondrogenesis \[[@B22-toxins-11-00667]\].

To study the HT-2 and T~3~ effects on gene expression, we selected 50 nM T~3~ and 50 nM HT-2, since the 50 nM concentration of HT-2 was the lowest concentration that decreased the cell viability of cultured chondrocytes. It was also noticed that the HT-2 toxin induced an increase in gene expression of *aggrecan* and *runx2* and a trend for increased expression of *type II collagen*. The expression of *type X collagen*, a marker for hypertrophic chondrocytes \[[@B23-toxins-11-00667]\], remained stable. Therefore, the cellular stage after HT-2 exposure can be considered to be pre-hypertrophic \[[@B18-toxins-11-00667]\]. The increased level of runx2 at the protein level confirmed the mRNA result.

As mentioned previously, such a strong response in *aggrecan* and *runx2* by HT-2 in comparison to the T~3~ effect was surprising, since T~3~ is known to induce hypertrophic differentiation. In tissue engineering applications, T~3~ has been shown to increase the expression and synthesis of type II collagen \[[@B24-toxins-11-00667]\], and improve articular cartilage surface architecture \[[@B25-toxins-11-00667]\]. As the metabolite of T-2 toxin, it would be reasonable to assume that the HT-2 toxin will share similarity with the T-2 toxin, which leads to cartilage destruction by the degradation of the extracellular matrix \[[@B26-toxins-11-00667],[@B27-toxins-11-00667]\]. In another study, the T-2 toxin promoted *aggrecanase-2* mRNA expression \[[@B28-toxins-11-00667]\]. The *ROS-NFκB-HIF-2α* pathway was shown to be essential for the catabolic effects of the T-2 toxin \[[@B29-toxins-11-00667]\]. However, in this cell culture model, it was not possible to confirm the possible anabolic or catabolic effects of HT-2 or T~3~ at the protein level due to the limited contents of extracellular matrix molecules secreted into the medium during the exposure time.

4. Conclusions {#sec4-toxins-11-00667}
==============

In conclusion, the HT-2 toxin led to significant cell death of human chondrocytes at rather low concentrations (threshold above 50 nM). Supplementation of T~3~ in cell culture medium decreased the cytotoxic effects of the HT-2 toxin only when it was applied in molar ratio 1:10, while other molar combinations failed to produce protective effects. The decrease in cell viability caused by the HT-2 toxin may be partly related to the finding that the cells appeared to shift quickly into a pre-hypertrophic state, indicated by an increased expression of *aggrecan* and *runx2*, and partly *collagen type II.* However, the major part of the HT-2 toxin effects is most likely due to its toxicity. Thus, further studies on the exact mechanism underlying the combined effect of T~3~ and HT-2 toxin on chondrocytes are warranted to provide a better understanding of the mechanism of HT-2 toxin cytotoxicity.

5. Materials and Methods {#sec5-toxins-11-00667}
========================

5.1. Chondrocyte Culture {#sec5dot1-toxins-11-00667}
------------------------

The immortalized human chondrocyte cell line C28/I2 was a kind gift from Dr. Mary B. Goldring (Hospital for Special Surgery, New York, NY, USA). Chondrocytes were cultured in Dulbecco's modified Eagle's medium (DMEM/F12; Hyclone, Logan, UT, USA), supplemented with 10% fetal bovine serum (FBS; Zhejiang Tianhang Biological Technology Stock Co., Huzhou, China), 100 U/mL penicillin/100 µg/mL streptomycin (Hyclone) at 37 °C and 5% CO~2~. During the culture period, the cells were passaged at subconfluency by sequential digestion in trypsin/EDTA (Hyclone; Sigma, St Louis, MO, USA), and the medium was replaced every 2 days \[[@B30-toxins-11-00667]\]. Three to four independent experiments were performed.

5.2. MTT Cytotoxicity Assay {#sec5dot2-toxins-11-00667}
---------------------------

Human chondrocytes C-28/I2 were seeded in 96-well plates at a density of 6.5 × 10^3^ cells/well. After incubation for 24 h, the culture medium was replaced to fresh medium (DMEM/F12 with 10% FBS and 1% penicillin and streptomycin) containing several mixture concentrations of T~3~ and/or HT-2 toxin ([Table 1](#toxins-11-00667-t001){ref-type="table"}), then treated for another 24 or 72 h. At the end of the intervention, the medium with T~3~ and/or HT-2 toxin was removed and replaced with fresh medium, and 20 μL aliquots of 5 mg/mL MTT stock solution (Amresco, Solon, OH, USA) were added into each well. After 4 h incubation in the presence of MTT to allow time for formazan formation, the medium was removed, and 150 μL dimethylsulfoxide was used to dissolve the formazan crystals from the wells. Optical densities of the samples were measured with a multi-plate reader (Infinite M200; Tecan Group, Männedorf, Switzerland) at a wavelength of 490 nm. The control groups included blank controls and normal controls. The blank control was fresh medium without the cells, and the normal control referred to the medium from the cell without T~3~ or the HT-2 toxin.

5.3. RNA Isolation and Quantitative Real-Time RT-PCR {#sec5dot3-toxins-11-00667}
----------------------------------------------------

Total RNA was isolated from the chondrocytes according to the manufacturer's protocols using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse-transcription was performed using PrimeScript™ RT Master Mix Kit (Takara, Kusatsu, Shiga, Japan). Real-time PCR reactions were conducted in the Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) using TB Green Premix Ex Taq™ II Kit (Takara), using the following parameters: 95 °C for 5 s, then 60 °C for 30 s, and 72 °C for 30 s, 40 cycles. The fold changes of relative gene expression were calculated with the 2^(−∆∆Ct)^ method \[[@B31-toxins-11-00667]\] using *GAPDH* as the reference gene. The primer sequences used in this study are shown in [Table 2](#toxins-11-00667-t002){ref-type="table"}.

5.4. Immunoblot Analysis {#sec5dot4-toxins-11-00667}
------------------------

The total protein was extracted from the cultured chondrocytes according to the manufacturer's protocols using an RIPA buffer (Beyotime, Shanghai, China). After denaturation, 30 μg of total protein was electrophoresed for immunoblot analysis. The blots were probed with primary antibodies directed against runx2 (Abcam, Cambridge, UK) overnight at 4 °C. GAPDH polyclonal antibody (Bioworld, Minneapolis, MN, USA) was used as a housekeeping reference. Peroxidase-conjugated goat anti-rabbit IgG (Thermo Fisher Scientific, Waltham, MA, USA) or goat anti-mouse IgG (Bioss, Shanghai, China) antibodies were used to visualize proteins using Western blotting chemiluminescence luminol reagent on a GeneGnome XRQ Western Blotting Analysis System (Syngene, Frederick, MD, USA). Working concentrations for each antibody were determined empirically based on the recommended stock solutions. Image J was used to quantify the band intensities of proteins of interest in the experimental and control groups.

5.5. Statistical Analysis {#sec5dot5-toxins-11-00667}
-------------------------

All experiments were performed three to four times. Parametric statistical analyses were selected to compare the effect of T3 and/or HT-2 toxin on C-28/I2 chondrocytes. One-way analysis of variance (ANOVA) was used to analyze the general difference, and the LSD-*t* (equal variances assumed) or Dunnett's T3-test (equal variances not assumed) post-hoc tests were used for further pairwise comparison with SPSS 13.0 (SPSS Inc., Chicago, IL, USA). The difference was considered statistically significant when the *p*-value was less than 0.05.

We thank Mary B. Goldring for donating the immortalized human chondrocyte cell line C-28/I2. We thank Daniel Marcellino, Umeå University for checking the language of the manuscript.

The following are available online at <https://www.mdpi.com/2072-6651/11/11/667/s1>, Figure S1: The dose-effect plot for [Figure 2](#toxins-11-00667-f002){ref-type="fig"} generated by CompuSyn software.
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![(**A**) Effect of T~3~ on viability of human C-28/I2 chondrocytes cultured for 24 and 72 h at T~3~ concentrations of 10, 50, 100, 500, and 1000 nM; (**B**) effect of HT-2 on human C-28/I2 chondrocytes cultured for 24 h at 0.1, 0.5, 1, 5, 10, 50, 100, 200, 500 1000, 5000, and 10,000 nM concentrations. The values show means ± SEM of three independent experiments. Cell viability of non-treated cultures in T~3~ experiments for 24 and 72 h were 100.0% ± 1.11% and 100.0% ± 10.06%, respectively, and in the HT-2 experiment, 100.0% ± 4.7%. Statistically significant differences against control cultures are indicated with asterisks, \* *p* \< 0.05 and \*\* *p* \< 0.01.](toxins-11-00667-g001){#toxins-11-00667-f001}

![Cytotoxicity of T~3~ and the HT-2 toxin. The ratios of HT-2:T~3~ were (**A**) 1:1, (**B**) 1:10, (**C**) 1:100, (**D**) 1:1000, (**E**) 10:1, (**F**) 100:1, and (**G**) 1000:1. The values are shown as means ± SEM of three independent experiments. The cell viability in the non-treated control cultures were (**A**) 100.0% ± 4.5%, (**B**) 100.0% ± 3.7%, (**C**) 100.0% ± 5.0%, (**D**) 100.0% ± 4.1%, (**E**) 100.0% ± 0.4%, (**F**) 100.0% ± 1.3%, and (**G**) 100.0% ± 5.4%. Statistically significant differences against control cultures are marked with asterisks, \* *p* \< 0.05 and \*\* *p* \< 0.01. The statistically significant differences observed between the HT-2 toxin and the mixture of the HT-2 toxin and T~3~ are also marked in (**E**--**G**). The amounts of T~3~ and HT-2 toxin for each mixture are provided in [Table 1](#toxins-11-00667-t001){ref-type="table"}.](toxins-11-00667-g002){#toxins-11-00667-f002}

![Gene expression levels of *collagen types II* and *X*, *aggrecan* and *runx2*, in C-28/I2 chondrocytes in control cultures and those treated with 50 nM T~3~ alone, 50 nM T~3~ plus 50 nM HT-2 toxin, and 50 nM HT-2 alone for 24 h. The fold changes are shown as mean ± SEM from three independent experiments. Statistically significant differences against control cultures are marked with asterisks, \* *p* \< 0.05 and \*\* *p* \< 0.01.](toxins-11-00667-g003){#toxins-11-00667-f003}

![Protein expression levels of runx2 in C-28/I2 chondrocytes in control cultures and those treated with 50 nM T~3~ alone, 50 nM T~3~ plus 50 nM HT-2 toxin, and 50 nM HT-2 alone for 24 h. The fold changes are shown as mean ± SEM from four independent experiments. Statistically significant differences against control cultures are marked with asterisks, \* *p* \< 0.05.](toxins-11-00667-g004){#toxins-11-00667-f004}

toxins-11-00667-t001_Table 1

###### 

The contents of the HT-2 toxin and T~3~ mixtures.

  Ratios       Components                                          Concentrations (nM)
  ------------ --------------------------------------------------- ------------------------------
  **1:1**      HT-2                                                1, 5, 10, 50, 100, 200, 500
  T~3~         1, 5, 10, 50, 100, 200, 500                         
  HT-2:T~3~    1:1, 5:5, 10:10, 50:50, 100:100, 200:200, 500:500   
  **1:10**     HT-2                                                1, 5, 10, 50, 100
  T3           10, 50, 100, 500, 1000                              
  HT-2:T~3~    1:10, 5:50, 10:100, 50:500, 100:1000                
  **1:100**    HT-2                                                1, 5, 10, 50, 100
  T~3~         100, 500, 10, 50, 100, 200, 500                     
  HT-2:T~3~    1:100, 5:500, 10:1000, 50:5000, 100:10,000          
  **1:1000**   HT-2                                                0.1, 0.5, 1, 5, 10
  T~3~         100, 500, 1000, 5000, 10,000                        
  HT-2:T~3~    0.1:100, 0.5:500, 1:1000, 5:5000, 10:10,000         
  **10:1**     HT-2                                                10, 50, 100, 500, 1000
  T~3~         1, 5, 10, 50, 100                                   
  HT-2:T~3~    10:1, 50:5, 100:10, 500:50, 1000:100                
  **100:1**    HT-2                                                10, 5,0 100, 500, 1000
  T~3~         0.1, 0.5, 1, 5, 10                                  
  HT-2:T~3~    10:0.1, 50:0.5, 100:1, 500:5, 1000:10               
  **1000:1**   HT-2                                                100, 500, 1000, 5000, 10,000
  T~3~         0.1, 0.5, 1, 5, 10                                  
  HT-2:T~3~    100:0.1, 500:0.5, 1000:1, 5000:5, 10,000:10         

toxins-11-00667-t002_Table 2

###### 

Specific primers for quantitative RT-PCR.

  Genes       Forward Primer             Reverse Primer
  ----------- -------------------------- ------------------------
  *COL2A1*    AGACTGGCGAGACTTGCGTCTA     ATCTCGGACGTTGGCAGTGTTG
  *ACAN*      CTGAACGACAGGACCATCGAA      CGTGCCAGATCATCACCACA
  *COL10A1*   GACTCATGTTTGGGTAGGCCTGTA   CCCTGAAGCCTGATCCAGGTA
  *Runx2*     AGCTTCTGTCTGTGCCTTCTGG     GGAGTGGACGAGGCAAGAGTTT
  *GAPDH*     GCACCGTCAAGGCTGAGAAC       TGGTGAAGACGCCAGTGGA
